Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.

Abstract

2.7-13.8); for radiation maculopathy location of posterior tumour margin within 2 mm from the fovea (HR 3.4, 95% CI 2.0-6.0); and for radiation optic neuropathy location of tumour margin within 1 DD of the optic disc (RR 6.1, 95% CI 3.0-12.4). The 3 and 5 year probabilities of avoiding enucleation were 92% and 85%, respectively. Ten eyes were enucleatedsix because of recurrent tumour growth, three because of treatment complications, and one because of mistakenly suspected extraocular growth.Conclusion-The results suggest that the frequency of radiation related complications after ruthenium brachytherapy of uveal melanoma is acceptable, in particular as regard irradiation of small and medium sized tumours for which ruthenium therapy generally is recommended. (Br_J Ophthalmol 1996;80:732-739)

Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanoma

“…The 5-year probability for eye preservation was 72% compared to 82% in a French [37], 83% in a Swedish [15], and 85% in a Finish series [27]. The tumours were larger than in the French and Swedish but similar to the Finish series.…”

Evidence-Based Estimates of Outcome in Patients Irradiated for Intraocular Melanoma

“…[31][32][33] Cataract extraction is feasible in these patients and can restore vision in some. [34][35][36] We found that panretinal photocoagulation can substantially reduce the severity of neovascular glaucoma and reduce the risk of enucleation by half (E.G., A.M.L., W.L., K.M.E., unpublished data, 2000).…”

Long‐term observations of a patient with choroidal melanoma following fractionated stereotactic radiotherapy: A case report

“…From our experience, doses exceeding 50-70 Gy used in these modalities may not be necessary (Tokuuye et al 1997). Radiation retinopathy is a frequent cause of visual acuity loss after ruthenium plaque radiotherapy (Summanen et al 1996), but in our patient, it occurred only in the limited area of the irradiated target, and as a result, his visual acuity was minimally affected. In patients treated with proton therapy, visual acuity evaluated at 3 years was preserved in twothirds of the patients, depending on the tumor size and location (Guyer et al 1992).…”